AIM To demonstrate whether bcl 2 gene can affect or alter biological behavior of a stomach carcinoma cell line MGC 803. METHODS To transduct a retrovirus containing bcl 2 antisense RNA to MGC 803 cells ...AIM To demonstrate whether bcl 2 gene can affect or alter biological behavior of a stomach carcinoma cell line MGC 803. METHODS To transduct a retrovirus containing bcl 2 antisense RNA to MGC 803 cells and then to analyse the Bcl 2 protein expression in the cells by Western blotting. To observe the morphology alteration, detect the G1 phase arrest by FCM, inhibition of proliferation by MTT method and tumorigenicity in nude mice. RESULTS The MGC anti bcl 2 cells shows contact inhibition, morphological alteration, from round or near round to shuttle like, decelerated growth rate, G1 phase arrest and weakened tumorigenicity in nude mice unlike the control (MGC neo cells). CONCLUSION Antisense RNA to bcl 2, not only can induce apoptosis, but also reverse the biological behavior of MGC 803 cells. This would be a potential application to the gene therapy for stomach cancers.展开更多
INTRODUCTIONVascular endothelial growth factor(VEGF)whichis also known as vascular permeability factor(VPF)is a heparin-binding,dimeric polypeptide growthfactor and a potent mitogen for endothelial cells.VEGF can stim...INTRODUCTIONVascular endothelial growth factor(VEGF)whichis also known as vascular permeability factor(VPF)is a heparin-binding,dimeric polypeptide growthfactor and a potent mitogen for endothelial cells.VEGF can stimulate the endothelial cell growth andenhance the motility through its two knownreceptors flt-1 and KDR.Acting through thesereceptors,VEGF may stimulate angiogenesis展开更多
AIM: To investigate the growth effects of 4-phenyl butyric acid (PBA) on human gastric carcinoma cells and their mechanisms. METHODS: Moderately-differentiated human gastric carcinoma SGC-7901 and lowly-differentiated...AIM: To investigate the growth effects of 4-phenyl butyric acid (PBA) on human gastric carcinoma cells and their mechanisms. METHODS: Moderately-differentiated human gastric carcinoma SGC-7901 and lowly-differentiated MGC-803 cells were treated with 5, 10, 20, 40, and 60 μmol/L PBA for 1-4 d. Cell proliferation was detected using the MTT colorimetric assay. Cell cycle distributions were examined using flow cytometry.RESULTS: The proliferation of gastric carcinoma cells was inhibited by PBA in a doseand time-dependent fashion. Flow cytometry showed that SGC-7901 cells treated with low concentrations of PBA were arrested at the G0/G1 phase, whereas cells treated with high concentrations of PBA were arrested at the G2/M phase. Although MGC-803 cells treated with low concentrations of PBA were also arrested at the G0/G1 phase, cells treated with high concentrations of PBA were arrested at the S phase. CONCLUSION: The growth inhibitory effect of PBA on gastric cancer cells is associated with alteration of the cell cycle. For moderately-differentiated gastric cancer cells, the cell cycle was arrested at the G0/G1 and G2/M phases. For lowly-differentiated gastric cancer cells, the cell cycle was arrested at the G0/G1 and S phases.展开更多
As a novel proteasome inhibitor, remarkable proliferation inhibitory effect of compound YSY-01A was shown on tumor cells in previous studies. However, few studies has reported its effect on gastric cancer and related ...As a novel proteasome inhibitor, remarkable proliferation inhibitory effect of compound YSY-01A was shown on tumor cells in previous studies. However, few studies has reported its effect on gastric cancer and related mechanism. We evaluated the anti-proliferative effect of compound YSY-01A using MGC-803 cells and its anti-tumor effect using xenograft nu-BALB/c mouse model. Cell proliferation inhibition was assessed by SRB assay. Related protein expression levels were determined by Western blot assay. We observed that the compound YSY-01A had a significant proliferation inhibitory effect on MGC-803 cells in vitro. Experiment in vivo showed that the compound YSY-01A had a remarkable growth inhibitory effect on MGC-803 cells xenograft tumor when it was used either alone or in combination with the conventional chemotherapeutic agent 5-fluorouracil （5-FU）. Furthermore, YSY-01A and 5-FU had a synergistic effect on xenograft tumor. Results of molecular experiment showed that the compound YSY-01A had a remarkable inhibitory effect on TNF-c~ and IFN induced NF-KB nuclear translocation. At the same time, the compound YSY-01A could reduce the expression of IKK-~, IL-I~ and iNOS, while it significantly enhanced the expression of COX-2 in MGC-803 ceils. Taken together, compound YSY-01A had an impressive tumor inhibitory effect, and it worked in NF-KB-related pathway, suggesting that the compound YSY-01A was an effective therapeutic drug for patients with gastric cancer. Higher tumor cell growth inhibition after the treatment in a combination with 5-FU indicated that combining YSY-01A with 5-FU might be more effective for displaying tumor cell growth inhibitory effects on gastric cancer cells.展开更多
文摘AIM To demonstrate whether bcl 2 gene can affect or alter biological behavior of a stomach carcinoma cell line MGC 803. METHODS To transduct a retrovirus containing bcl 2 antisense RNA to MGC 803 cells and then to analyse the Bcl 2 protein expression in the cells by Western blotting. To observe the morphology alteration, detect the G1 phase arrest by FCM, inhibition of proliferation by MTT method and tumorigenicity in nude mice. RESULTS The MGC anti bcl 2 cells shows contact inhibition, morphological alteration, from round or near round to shuttle like, decelerated growth rate, G1 phase arrest and weakened tumorigenicity in nude mice unlike the control (MGC neo cells). CONCLUSION Antisense RNA to bcl 2, not only can induce apoptosis, but also reverse the biological behavior of MGC 803 cells. This would be a potential application to the gene therapy for stomach cancers.
基金National Distinguished Young Scientist Fund,39525021 State Key Basic Research Program G1998051203
文摘INTRODUCTIONVascular endothelial growth factor(VEGF)whichis also known as vascular permeability factor(VPF)is a heparin-binding,dimeric polypeptide growthfactor and a potent mitogen for endothelial cells.VEGF can stimulate the endothelial cell growth andenhance the motility through its two knownreceptors flt-1 and KDR.Acting through thesereceptors,VEGF may stimulate angiogenesis
基金Supported by Natural Science Foundation of Ningbo, No. 2009A610134Natural Sciences Foundation of Zhejiang, No. Y207244+3 种基金College Students’ Science-Technology Innovation Program of Zhejiang Province, No. 200959the Excellent Disser-tation Foundation of Ningbo University, No. 201014KC Wong Magna Fund of Ningbo Universitythe Scientific Innovation Team Project of Ningbo, No.2011B82014
文摘AIM: To investigate the growth effects of 4-phenyl butyric acid (PBA) on human gastric carcinoma cells and their mechanisms. METHODS: Moderately-differentiated human gastric carcinoma SGC-7901 and lowly-differentiated MGC-803 cells were treated with 5, 10, 20, 40, and 60 μmol/L PBA for 1-4 d. Cell proliferation was detected using the MTT colorimetric assay. Cell cycle distributions were examined using flow cytometry.RESULTS: The proliferation of gastric carcinoma cells was inhibited by PBA in a doseand time-dependent fashion. Flow cytometry showed that SGC-7901 cells treated with low concentrations of PBA were arrested at the G0/G1 phase, whereas cells treated with high concentrations of PBA were arrested at the G2/M phase. Although MGC-803 cells treated with low concentrations of PBA were also arrested at the G0/G1 phase, cells treated with high concentrations of PBA were arrested at the S phase. CONCLUSION: The growth inhibitory effect of PBA on gastric cancer cells is associated with alteration of the cell cycle. For moderately-differentiated gastric cancer cells, the cell cycle was arrested at the G0/G1 and G2/M phases. For lowly-differentiated gastric cancer cells, the cell cycle was arrested at the G0/G1 and S phases.
基金Eleventh Five-Year Plan for National Science and Technology Major Project(Grant No.2009ZX0930-010)National Science Foundation of China(Grant No.81172915)a grant from Major New Drug Research and Development Platform of PekingUniversity(Grant No.2009ZX09301-010)
文摘As a novel proteasome inhibitor, remarkable proliferation inhibitory effect of compound YSY-01A was shown on tumor cells in previous studies. However, few studies has reported its effect on gastric cancer and related mechanism. We evaluated the anti-proliferative effect of compound YSY-01A using MGC-803 cells and its anti-tumor effect using xenograft nu-BALB/c mouse model. Cell proliferation inhibition was assessed by SRB assay. Related protein expression levels were determined by Western blot assay. We observed that the compound YSY-01A had a significant proliferation inhibitory effect on MGC-803 cells in vitro. Experiment in vivo showed that the compound YSY-01A had a remarkable growth inhibitory effect on MGC-803 cells xenograft tumor when it was used either alone or in combination with the conventional chemotherapeutic agent 5-fluorouracil （5-FU）. Furthermore, YSY-01A and 5-FU had a synergistic effect on xenograft tumor. Results of molecular experiment showed that the compound YSY-01A had a remarkable inhibitory effect on TNF-c~ and IFN induced NF-KB nuclear translocation. At the same time, the compound YSY-01A could reduce the expression of IKK-~, IL-I~ and iNOS, while it significantly enhanced the expression of COX-2 in MGC-803 ceils. Taken together, compound YSY-01A had an impressive tumor inhibitory effect, and it worked in NF-KB-related pathway, suggesting that the compound YSY-01A was an effective therapeutic drug for patients with gastric cancer. Higher tumor cell growth inhibition after the treatment in a combination with 5-FU indicated that combining YSY-01A with 5-FU might be more effective for displaying tumor cell growth inhibitory effects on gastric cancer cells.
